• La comunità scientifica italiana (area “life sciences”) e
la sfida dei progetti comunitari
applications
1.600
1.400
1.200
1.000
800
600
400
200
0
DE UK IT FR NL ES SE BE DK PL Fi AT GR HU CZ PT IE EE SI SK LT CY LV Lu MT
percentuale di successo
40,00%
35,00%
30,00%
25,00%
20,00%
15,00%
10,00%
5,00%
0,00%
EU BE FR UK IE NL DE AT DK IT SE ES Fi PT HU EE GR CZ LT CY SI PL Lu SK LV MT
percentuale di partecipazione
di ricercatori italiani
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
UNI
REC
SME
IND
OTHER
percentuale di partecipazione
70%
60%
50%
40%
IT
30%
20%
10%
0%
FR
UNI
REC
SME
IND
OTHER
percentuale di successo
40,00%
35,00%
30,00%
25,00%
20,00%
15,00%
10,00%
5,00%
0,00%
All
UNI
REC
SMEs
IND
Other
La specializzazione scientifica italiana e relativa
valutazione dei punti di forza
Alf onso Gambardella
UniversitˆBocconi, Milano
&
Aldo Geuna
SPRU, Un iversity of Sussex & RSCAS, European University Institute
Specializzazione scientifica Italiana - Pubblicazioni
Symmetric Relative Specialization Index (RSI)
0,200
0,000
-0,200
-0,400
1992-1994
1998-2000
Gastroenterology and Hepatology
Hematology
Oncogenesis & Cancer Research
Oncology
Pharmacology/Toxicology
Space Science
Instrumentation/Measurement
Physics
Inorganic&Nuclear Chemistry
-0,600
-0,800
-1,000
01
02
03
04
05
06
07
08
09
Aree disciplinari
10
11
12
13
14
• La comunità scientifica italiana (area “life sciences”) e
la sfida dei progetti comunitari
• I temi su cui abbiamo più probabilità di ottenere finanziamenti
• La comunità scientifica italiana (area “life sciences”) e
la sfida dei progetti comunitari
• I temi su cui abbiamo più probabilità di ottenere finanziamenti
• Cosa chiede la comunità scientifica
a) incrementare i finanziamenti;
b) eliminare l’obbligo di creare networks di ricerca per accedere ai
finanziamenti a meno che non esistano delle reali esigenze di collaborazione;
c) offrire spazi significativi al finanziamento di nuovi gruppi di ricerca;
d) riservare una quota significativa delle risorse al finanziamento di progetti di
ricerca liberi, cioè non finalizzati al raggiungimento di obiettivi preordinati;
e) dare spazio alla mobilità dei ricercatori, non limitandola alle attività di
formazione.
i) uniformità delle politiche di finanziamento pubblico;
ii) coordinamento delle politiche di finanziamento nazionali e europee;
iii) incentivi alla mobilità transnazionale dei group leaders;
iv) accesso a tutti i ricercatori europei alle fonti di finanziamento delle singole nazioni.
Collaborative research will constitute the bulk and the core of EU research funding
Joint Technology Initiatives will mainly be created on the basis of the work
undertaken by the European Technology Platforms
- Emphasis on research themes rather than on “instruments”
- Significant simplification of its operation
- Focus on developing research that meets the needs of European industry, through the work of
Technology Platforms and the new Joint Technology Initiatives
- Establishment of a European Research Council, funding the best of European science
- Integration of International cooperation in all four programmes
- Development of Regions of Knowledge
- A Risk-Sharing Finance Facility aimed at fostering private investment in research
Lower number of partners in consortia and a greater focus on smaller projects
Proposal for a
COUNCIL DECISION
concerning the Specific Programme “Cooperation” implementing the Seventh
Framework Programme (2007-2013) of the European Community for research,
technological development and demonstration activities
Biotechnology, generic tools and technologies for human health
This activity aims at developing and validating the necessary tools and technologies that will make possible the production of
new knowledge and its translation into practical applications in the area of health and medicine.
–
High-throughput research
The focus will be on new technologies for: sequencing; gene expression, genotyping and phenotyping; structural genomics;
bioinformatics and systems biology; other “omics”.
–
Detection, diagnosis and monitoring:
The focus will be on a multidisciplinary approach integrating areas such as: molecular and cellular biology, physiology,
genetics, physics, chemistry, nanotechnologies, microsystems, devices and information technologies. Non- or minimallyinvasive and quantitative methods and quality assurance aspects will be emphasised.
–
Innovative therapeutic approaches and interventions:
The focus will be on gene and cell therapy, regenerative medicine, transplantation, immunotherapy and vaccines, and other
medicines. Related technologies, such as advanced targeted delivery systems, advanced implants and prosthetics, and nonor minimally-invasive technology-assisted interventions will also be addressed.
–
Predicting suitability, safety and efficacy of therapies
The focus will be on approaches such as pharmacogenomics, in silico, in vitro (including alternatives to animal testing) and in
vivo methods and models.
Translating research for human health
This activity aims at increasing knowledge of biological processes and mechanisms involved in normal health and in specific
disease situations, to transpose this knowledge into clinical applications, and to ensure that clinical data guide further
research.
– Integrating biological data and processes: large-scale data gathering, systems biology.
Large scale data gathering: The focus will be on: genomics; proteomics; population genetics; comparative and
functional genomics.
- Systems biology: the focus will be on multidisciplinary research that will integrate a wide variety of biological
data and will develop and apply system approaches to understand and model biological processes.
– Research on the brain and related diseases, human development and ageing.
Brain and brain-related diseases
The focus will be to explore brain functions, from molecules to cognition, and to address neurological and
psychiatric diseases and disorders, including regenerative and restorative therapeutic approaches.
Human development and ageing:
The focus will be on the study of human and model systems, including interactions with factors such as
environment, behaviour and gender.
– Translational research in major infectious diseases: to confront major threats to public health.
Anti-microbial drug resistance: the focus will be on combining basic research on molecular mechanisms of
resistance, microbial ecology and host-pathogen interactions with clinical research towards new interventions to
reduce the emergence and spread of multi-drug resistant infections.
HIV/AIDS, malaria and tuberculosis: the focus will be on developing new therapies, diagnostic tools, preventive
vaccines and chemical transmission barriers such as HIV microbicides
Emerging epidemics: the focus will be on confronting emerging pathogens with pandemic potential including
zoonoses (e.g. SARS and highly pathogenic influenza).
– Translational research in other major diseases.
Cancer
Cardiovascular disease
Diabetes and obesity
Rare diseases
Other chronic diseases
Optimising the delivery of health care to European citizens
This activity aims at providing the necessary basis both for informed policy decisions on health systems and for more
effective strategies of health promotion, disease prevention, diagnosis and therapy.
– Enhanced health promotion and disease prevention:
– Translating clinical research into clinical practice
– Quality, solidarity and sustainability of health systems